Genedata Biologics enables data-driven decisions. With outstanding capabilities for sequence annotation and sample traceability, error-prone manual processes can be eliminated, which greatly facilitates our laboratory operations.
BASEL, Switzerland (PRWEB) January 27, 2021
Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Teva Pharmaceuticals Inc., a multinational pharmaceutical company developing high-quality generics and specialty medicines, has broadened the usage and applications of Genedata Biologics® to advance operational excellence in Teva’s R&D organization. After integrating the Genedata platform with Teva’s laboratory instruments and automation systems, Teva scientists are now using the Genedata platform to drive automation and further accelerate discovery operations.
“By capturing the increasing amounts of biologics R&D data and compiling this information across our R&D workflows in a centralized location, Genedata Biologics enables data-driven decisions and allows us to gain deeper insights into our data so we can identify the most promising drug candidates. With outstanding capabilities for sequence annotation and sample traceability, error-prone manual processes can be eliminated, which greatly facilitates our laboratory operations,” said Sachin Surade, Ph.D., Director, Antibody Generation, of Teva Pharmaceuticals. “Genedata Biologics aids informed decision-making to help get the best biopharma lead candidates faster to the clinic.”
The Genedata platform is Teva’s backbone system for capturing and consolidating records of all antibody candidates so that every team member can systematically trace complete information on any molecule or sample to gain insight and guide decision-making. The Genedata platform has also been configured for Teva-specific workflows, which has helped to establish standardized processes for enhanced reproducibility and data comparability at Teva, a critical pre-requisite to enable informed decisions based on complex, large R&D datasets.
Genedata Biologics integrates and digitalizes Teva’s biopharma R&D workflows, significantly enhancing efficiency and quality of biopharma R&D processes. To facilitate and automate data capture, it has been directly integrated with lab automation platforms to generate, process, and test huge numbers of samples and molecules, enabling true high-throughput R&D operations. Genedata Biologics compares data for candidates resulting from a variety of discovery technologies, such as for B-cells, hybridoma, or library display workflows.
“The biopharma industry is currently undergoing a dramatic change as companies around the globe are pushing for the industrialization of their R&D processes. Workflow automation is a key element in this transformation, and we are proud to support Teva by automating their biopharma R&D processes,” said Othmar Pfannes, Ph.D., CEO of Genedata. “We are committed to driving efficiencies in biopharma discovery and development, which helps our customers develop better therapies faster.”
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.
LinkedIn | Twitter | YouTube
Phone: +41 61 511 85 61
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.